Inflammasomes are cytosolic innate immune sensors of pathogen
infection and cellular damage that induce caspase-1-mediated
inflammation upon activation. Although
inflammation is protective, uncontrolled excessive
inflammation can cause inflammatory diseases and can be detrimental, such as in coronavirus disease (COVID-19). However, the underlying mechanisms that control
inflammasome activation are incompletely understood. Here we report that the
leucine-rich repeat (LRR)
protein ribonuclease inhibitor (RNH1), which shares homology with LRRs of NLRP (
nucleotide-binding oligomerization domain,
leucine-rich repeat, and pyrin domain containing)
proteins, attenuates
inflammasome activation. Deletion of RNH1 in macrophages increases
interleukin (IL)-1β production and caspase-1 activation in response to
inflammasome stimulation. Mechanistically, RNH1 decreases pro-IL-1β expression and induces
proteasome-mediated caspase-1 degradation. Corroborating this, mouse models of
monosodium urate (MSU)-induced
peritonitis and
lipopolysaccharide (LPS)-induced
endotoxemia, which are dependent on caspase-1, respectively, show increased neutrophil infiltration and lethality in Rnh1 -/- mice compared with wild-type mice. Furthermore, RNH1
protein levels were negatively related with disease severity and
inflammation in hospitalized
COVID-19 patients. We propose that RNH1 is a new
inflammasome regulator with relevance to
COVID-19 severity.